Diabetic Gastroparesis Treatment Market, By Product Type (Drugs (Gastroprokinetic Agents, Antiemetic Agents, Botulinum Toxin), Surgical Treatment Products (Gastric Electrical Stimulation (GES) Device, Percutaneous Endoscopic Gastrostomy (PEG) Kit, Parente

Gastroparesis is the delaying of gastric emptying without any evidence of mechanical obstruction. Diabetic gastroparesis is a potential complication that occurs in the setting of poorly controlled diabetes, resulting from dysfunction in the coordination and function of the autonomic nervous system, neurons, and specialized pacemaker cells of the stomach and intestine, and the smooth muscle cells of the gastrointestinal tract. Diabetic gastroparesis occurs as a result of dysfunction in the autonomic and enteric nervous systems. Chronically high levels of blood glucose (or inefficient glucose uptake) lead to neuronal damage resulting in abnormal myenteric neurotransmission, impaired inhibitory neuronal function, and dysfunctional smooth muscle and pacemaker cells of stomach.

Altogether, this dysfunction results in a combination of fewer contractions of the antrum, uncoordinated antro-duodenal contractions, and pyloric spasms, ultimately resulting in delayed gastric emptying (gastroparesis). Delayed gastric emptying in patients with diabetes, particularly of solids, may also occur in the setting of abnormal small bowel motility, which is thought to occur by a similar mechanism as that which is described in the stomach. Some patients with diabetes may additionally experience changes in gastric compliance, both increased or decreased, which may also contribute to delayed gastric emptying.

Market Dynamics

Increasing prevalence of diabetes worldwide, increasing geriatric population and sedentary lifestyle, increasing affordability and accessibility of medication to patients, and research and development activities on diabetic gastroparesis attributed to the growth of global diabetic gastroparesis treatment market. For instance, on June 23, 2020, Evoke Pharma, a U.S.-based pharmaceutical company, announced that the U.S. Food And Drug Administration has approved the new drug application for Gimoti nasal spray to relieve symptoms in adults with acute and recurrent diabetic gastroparesis. The drug, Metoclopramide has limited use due to associated side effects. Hence, a novel approach by introducing drug in trans nasal pathway is taken.

Key features of the study:

• This report provides an in-depth analysis of the Global Diabetic Gastroparesis Treatment Market and provides market size (US$ Million) and compound annual growth rate (CAGR) for the forecast period 2025-2032, considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global diabetic gastroparesis market based on the following parameters–Company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Janssen Global Services, LLC, Cardinal Health, Inc., Evoke Pharma, Inc., Salix Pharmaceuticals, Inc., Alfa Wassermann SPA, Abbott Laboratories, Medtronic Plc., C. R. Bard, Inc. (Becton, Dickinson and Company), Rhythm Pharmaceuticals, Inc., Boston Scientific Corporation, Kimberly-Clark Corporation, Vanda Pharmaceuticals, Inc., and Allergan, plc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global diabetic gastroparesis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global diabetic gastroparesis treatment market

• Global Diabetic Gastroparesis Treatment Market, By Product Type:
• Drugs
• Gastroprokinetic Agents
• Antiemetic Agents
• Botulinum Toxin
• Surgical Treatment Products
• Gastric Electrical Stimulation (GES) Device
• Percutaneous Endoscopic Gastrostomy (PEG) Kit
• Parenteral Nutrition
• Global Diabetic Gastroparesis Treatment Market, By Disease Indication:
• Compensated Gastroparesis
• Gastric Failure
• Global Diabetic Gastroparesis Treatment Market, By Distribution channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Diabetic Gastroparesis Treatment Market, By Region:
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC
• Israel
• Rest of Middle East
• Africa
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Janssen Global Services
• LLC, Cardinal Health, Inc.
• Evoke Pharma, Inc.
• Salix Pharmaceuticals, Inc.
• Alfa Wassermann SPA
• Abbott Laboratories
• Medtronic Plc.,
• C.R. Bard, Inc. (Becton, Dickinson and Company)
• Rhythm Pharmaceuticals, Inc.
• Boston Scientific Corporation
• Kimberly-Clark Corporation
• Vanda Pharmaceuticals, Inc.
• Allergan, plc.